thecardiologyadvisor.com4d
Nasal Spray Formulation of Bumetanide Under FDA Review
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
Inquirer on MSN3d
World’s first anti-depression nasal spray receives FDA approval
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...
BioSpace4d
GH’s Inhaled Psychedelic Succeeds in Mid-Stage Depression Trial
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
New Hampshire Public Radio4d
Health experts alarmed at new overdose drug marketed to WMass police departments
Public health experts have concerns about the opioid reversal agent Opvee. But the company that makes it, Indivior, has found ...